• Marketing outside the box

    There’s ever-increasing menu of tools, technologies and tactics to choose from, but is pharma ready to innovate?

  • The impact of a 'hard Brexit'

    In January, the prime minister, Theresa May, warned the EU that “no deal for Britain is better than a bad deal” when it comes to Brexit. Although her government is now edging away from that position, the statement raised the question of what no deal would actually mean for the pharma industry

  • Genetic data

    Are the muddled laws and ethical questions surrounding privacy of genetic data impeding pharma research?

  • Empowering technology

    How patient empowerment could change healthcare and pharma at the most fundamental level

  • Finalists for International Clinical Researcher of the Year 2017 announced

    PharmaTimes Media is delighted to report that once again, clinical researchers from across the globe have engaged with the International Clinical Researcher of the Year competition.

News

View all
Thumbnail image for CHMP backs 11 medicines for European approval

CHMP backs 11 medicines for European approval

Eleven new medicines have taken a giant leap towards approval in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Product for Human Use (CHMP), including two that treat rare neurodegenerative conditions in children.

24th April 2017

Thumbnail image for US green light for Remicade biosimilar

US green light for Remicade biosimilar

US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications.

24th April 2017

Thumbnail image for Pharma heads call for decision on EMA relocation

Pharma heads call for decision on EMA relocation

Pharma chiefs in Europe are calling on heads of state to reach a prompt decision on the new location for the European Medicines Agency, which is to depart from the UK as a result of Brexit.

24th April 2017

Thumbnail image for BMS presents promising data for NASH drug

BMS presents promising data for NASH drug

Bristol-Myers Squibb’s investigational liver disease candidate has hit its targets in a mid-stage trial, supporting further research on the drug as a potential treatment for Nonalcoholic Steatohepatitis (NASH).

24th April 2017

Thumbnail image for The impact of a 'hard Brexit'

The impact of a 'hard Brexit'

In January, the prime minister, Theresa May, warned the EU that “no deal for Britain is better than a bad deal” when it comes to Brexit. Although her government is now edging away from that position, the statement raised the question of what no deal would actually mean for the pharma industry

Thumbnail image for Marketing outside the box

Marketing outside the box

There’s ever-increasing menu of tools, technologies and tactics to choose from, but is pharma ready to innovate?

Thumbnail image for Genetic data

Genetic data

Are the muddled laws and ethical questions surrounding privacy of genetic data impeding pharma research?

Thumbnail image for Trials and tribulations

Trials and tribulations

As pharma grapples the twin challenge of developing breakthrough innovations while reducing development costs, the contract research market continues to provide vital support. CRO leaders are well-positioned to spot the trends that are shaping clinical trials in 2017. Here are six of the best…

Thumbnail image for Pick 'n' mix

Pick 'n' mix

The future of pharma's salesforce has been a hotly debated topic for years. Now we wave goodbye to one-size-fits-all and embrace a field force fusion

Thumbnail image for Critical communications

Critical communications

The fight against flu – and the need for clear lines of communications between the NHS and the public – provides a case study for public health

Thumbnail image for Empowering technology

Empowering technology

How patient empowerment could change healthcare and pharma at the most fundamental level

Thumbnail image for Through thick and thin

Through thick and thin

In an increasingly competitive market where patient-centricity is key, enhancing customer experience to improve loyalty could be pharma's next big step forward

Webinars

View all

Designing Pharma organisations for success

Across all industries, people are changing the ways they engage with products, services, and brands. View more...

Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download